GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crinetics Pharmaceuticals Inc (NAS:CRNX) » Definitions » Book Value per Share

Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Book Value per Share : $11.14 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Crinetics Pharmaceuticals Book Value per Share?

Crinetics Pharmaceuticals's book value per share for the quarter that ended in Mar. 2024 was $11.14.

During the past 12 months, Crinetics Pharmaceuticals's average Book Value Per Share Growth Rate was 114.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 15.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Crinetics Pharmaceuticals was 15.60% per year. The lowest was 1.60% per year. And the median was 6.70% per year.

Crinetics Pharmaceuticals's current price is $47.47. Its book value per share for the quarter that ended in Mar. 2024 was $11.14. Hence, today's PB Ratio of Crinetics Pharmaceuticals is 4.26.

During the past 8 years, the highest P/B Ratio of Crinetics Pharmaceuticals was 6.40. The lowest was 2.49. And the median was 3.44.


Crinetics Pharmaceuticals Book Value per Share Historical Data

The historical data trend for Crinetics Pharmaceuticals's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crinetics Pharmaceuticals Book Value per Share Chart

Crinetics Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial 4.83 5.12 6.97 5.87 7.91

Crinetics Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.19 4.65 8.21 7.91 11.14

Competitive Comparison of Crinetics Pharmaceuticals's Book Value per Share

For the Biotechnology subindustry, Crinetics Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crinetics Pharmaceuticals's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's PB Ratio falls into.



Crinetics Pharmaceuticals Book Value per Share Calculation

Crinetics Pharmaceuticals's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(539.11-0.00)/68.18
=7.91

Crinetics Pharmaceuticals's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(874.93-0.00)/78.54
=11.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Crinetics Pharmaceuticals  (NAS:CRNX) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Crinetics Pharmaceuticals Book Value per Share Related Terms

Thank you for viewing the detailed overview of Crinetics Pharmaceuticals's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Crinetics Pharmaceuticals (Crinetics Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
10222 Barnes Canyon Road, Building No. 2, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Executives
Stephen F. Betz officer: Chief Scientific Officer 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Dana Pizzuti officer: Chief Development Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Marc Wilson officer: See Remarks 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Richard Scott Struthers director, officer: See Remarks C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Alan Seth Krasner officer: Chief Medical Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Vivaldi Coelho Rogerio director 225 SECOND AVENUE, WALTHAM MA 02451
Jeff E. Knight officer: Chief Operating Officer CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BUILDING 2, SAN DIEGO CA 92121
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Caren Deardorf director C/O MAGENTA THERAPEUTICS, INC., 100 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James Hassard officer: Chief Commercial Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Ajay Madan officer: Chief Development Officer C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. 2, SAN DIEGO CA 92121
Camille L Bedrosian director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003